Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the Conference on Retroviruses and Opportunistic Infection. The trials showed modest protection reducing rates of HIV acquisition by around one-third overall with greater effect in women over 21 who had higher adherence. Below, please find press releases, background information and other useful resources about the Ring and ASPIRE studies.
Press Releases
- International Partnership for Microbicides Press Release
- Microbicide Trials Network Press Release
- AVAC Press Release
- CAPRISA Press Release
- CONRAD Press Release
- IAVI Press Release
- ICWEA Press Release
- International HIV/AIDS Alliance Press Release
- NIAID Press Release
- Population Council Press Release
- SAMRC Press Release
- UNAIDS Press Release
Webcast/Webinars
- Click for the presentations of the ASPIRE and Ring Study results.
- AVAC hosted a post-CROI webinar with with Jared Baeten (MTN) and Zeda Rosenberg (IPM) where they presented their results and fielded questions from webinar participants; click here.
Background Information
Materials from IPM and MTN
Peer-Reviewed Articles
- Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women — New England Journal of Medicine
Highlighted News and Blogs
- Vaginal Ring Could Cut HIV Risk by 27-31 Percent — Scidev
- Innovative HIV Prevention Product for Women Could be New Tool in the Fight for an AIDS Free Generation — USAID Impact Blog
- Vaginal Ring Offers Partial HIV Protection — Health-E News
- Vaginal Rings Containing Antiretroviral Moderately Effective in Preventing HIV – but not in the youngest women — aidsmap
- A Vaginal Ring Could Prevent HIV, Two Huge Studies Just Found — BuzzFeed
- Drug-laced Vaginal Ring Succeeds Against HIV- Sometimes — Science
Infographics
Download a PDF version of the table here.
To help understand these infographics, plesae see our Advocates' Guide to Statistical Terms.